WEB Assessing PBC Treatment Options Determining Sequencing
Understanding PBC Treatment Guidance
In 2018, the European Medicine Agency EMA updated its guidance on primary biliary cholangitis (PBC), including information on etiology, diagnosis, clinical manifestations, and treatment.
This updated guidance provides valuable information for healthcare professionals managing PBC patients.
Treatment Sequencing in PBC
Treatment sequencing in PBC has evolved over time with the emergence of new therapies.
In this video segment, Reau Trivedi and Hirschfield discuss the EMA opinion on treatment sequencing in PBC.
Ursodeoxycholic Acid (UDCA)
First-line treatment for PBC involves the initiation of ursodeoxycholic acid (UDCA).
UDCA is a bile acid that helps protect liver cells from damage and improve bile flow.
Combination Therapies
In some cases, combination therapies may be used to improve treatment outcomes.
- The BEZURSO study by Corpechot et al assessed the efficacy of combination treatment of standard dose UDCA with bezafibrate.
- Combination therapies may offer additional benefits, such as reducing liver inflammation and improving liver function.
Komentar